BIOFIRE BCID2 面板多中心评估:阳性血培养中细菌、酵母及耐药基因检测
该研究评估 BIOFIRE BCID2 面板在阳性血培养样本中检测细菌、酵母及耐药基因的性能,与标准方法、测序、PCR 及参考药敏结果比较。最终分析 1,074 份样本,总体灵敏度 98.9%(1,712/1,731),特异度 99.6%(33,592/33,711),耐药决定簇 PPA 97.9%(325/332)、NPA 99.9%(2,465/2,767)。结论认为该面板在临床试验中产生准确结果。
要点
- BCID2 面板对目标细菌和酵母检测总体灵敏度 98.9%、特异度 99.6%。
- 耐药决定簇总体 PPA 97.9%、NPA 99.9%。
- 肠杆菌目耐药标记存在与否与表型药敏高度相关。
核心结论
- BIOFIRE BCID2 面板在临床试验中产生准确结果,可快速鉴定阳性血培养中的微生物及耐药基因。
研究设计与样本
- 多中心临床研究,比较 BIOFIRE BCID2 面板与标准方法、测序、PCR 及参考实验室药敏结果。
- 初始入组 1,093 份回顾性和前瞻性收集的阳性血培养样本,1,074 份符合标准纳入最终分析。
主要发现
- 对面板设计检测的革兰阳性菌、革兰阴性菌和酵母目标,总体灵敏度 98.9%(1,712/1,731),总体特异度 99.6%(33,592/33,711)。
- 对面板设计检测的耐药决定簇,总体 PPA 97.9%(325/332),总体 NPA 99.9%(2,465/2,767)。
- 肠杆菌目中耐药标记的存在或缺失与表型敏感性和耐药性高度相关。
临床怎么用
- 可快速提供阳性血培养中微生物鉴定和耐药基因信息,辅助优化患者管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnostic tools that can rapidly identify and characterize microbes growing in blood cultures are important components of clinical microbiology practice because they help to provide timely information that can be used to optimize patient management. This publication describes the bioMérieux BIOFIRE Blood Culture Identification 2 (BCID2) Panel clinical study that was submitted to the U.S. Food & Drug Administration. Results obtained with the BIOFIRE BCID2 Panel were compared to standard-of-care (SoC) results, sequencing results, PCR results, and reference laboratory antimicrobial susceptibility testing results to evaluate the accuracy of its performance. Results for 1,093 retrospectively and prospectively collected positive blood culture samples were initially enrolled, and 1,074 samples met the study criteria and were included in the final analyses. The BIOFIRE BCID2 Panel demonstrated an overall sensitivity of 98.9% (1,712/1,731) and an overall specificity of 99.6% (33,592/33,711) for Gram-positive bacteria, Gram-negative bacteria and yeast targets which the panel is designed to detect. One hundred eighteen off-panel organisms, which the BIOFIRE BCID2 Panel is not designed to detect, were identified by SoC in 10.6% (114/1,074) of samples. The BIOFIRE BCID2 Panel also demonstrated an overall positive percent agreement (PPA) of 97.9% (325/332) and an overall negative percent agreement (NPA) of 99.9% (2,465/2,767) for antimicrobial resistance determinants which the panel is designed to detect. The presence or absence of resistance markers in Enterobacterales correlated closely with phenotypic susceptibility and resistance. We conclude that the BIOFIRE BCID2 Panel produced accurate results in this clinical trial.
引用
- Rhoads DD, Pournaras S, Leber A, et al. Multicenter Evaluation of the BIOFIRE Blood Culture Identification 2 Panel for Detection of Bacteria, Yeasts, and Antimicrobial Resistance Genes in Positive Blood Culture Samples. J Clin Microbiol. 2023. PMID: 37227281. doi:10.1128/jcm.01891-22
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。